Friends publishes commentary in Science Translational Medicine and Whitepaper Report on patient-centered drug development. Links below:
AAAS' Science Translational Medicine
Friends Whitepaper - Enhancing Use of Patient-Centered Data in Regulatory Decision Making
Friends Honors Rep. Fred Upton, Rep. Diana DeGette, and President Marlene Malek as Dr. Francis Collins sings, "If Not Now, Tell Me When"
Ellen Sigal Calls for updated FDA structure for 21st Century science and patient needs
Friends of Cancer Research and the Engelberg Center for Health Care Reform at Brookings co-hosted discussions on critical issues in cancer care.
Friends of Cancer Research is our country's leading voice in advocating for policies and solutions that will get treatments to patients in the safest and quickest way possible.
Researchers, drug developers, and patient advocates share their thoughts about Lung-MAP
The FDA's Breakthrough Therapy program continues to accelerate the development and approval of groundbreaking new therapies.
Sacituzumab govitecan (IMMU-132) - (Immunomedics)
for the treatment of patients with triple-negative breast cancer (TNBC) following at least 2 treatments for metastatic disease
Venetoclax - (AbbVie/Roche)
for the treatment of patients with untreated (treatment-naïve) acute myeloid leukemia (AML) who are ineligible to receive standard induction therapy (high-dose chemotherapy)
FRIENDS OF CANCER RESEARCH1800 M Street NW Suite 1050 | Washington, DC 20036202.944.6700